Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial

María‐Victoria Mateos, Hilary Blacklock, Fredrik Schjesvold, +117

The Lancet Haematology

Hematological MalignancyOncologyHematologyImmunologyImmune Checkpoint Inhibitor +4

Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial

Saad Z. Usmani, Fredrik Schjesvold, Albert Oriol, +114

The Lancet Haematology

Hematological MalignancyMedicineImmunologyClinical TrialsHematology +5

Coagulation-induced shedding of platelet glycoprotein VI mediated by factor Xa

Mohammad Al‐Tamimi, George Grigoriadis, Huy Tran, +5

Blood

IMiDs prime myeloma cells for daratumumab-mediated cytotoxicity through loss of Ikaros and Aiolos

Pasquale L. Fedele, Simon N. Willis, Yang Liao, +10

Blood

The Transcription Factors c-rel and RelA Control Epidermal Development and Homeostasis in Embryonic and Adult Skin via Distinct Mechanisms

Raffi Gugasyan, Anne K. Voss, George Varigos, +5

Molecular and Cellular Biology

Distinct MechanismsCell ProliferationAdult SkinDermatologyEpigenetics +17

IRF4 Activity Is Required in Established Plasma Cells to Regulate Gene Transcription and Mitochondrial Homeostasis

Michael Löw, Erica J. Brodie, Pasquale L. Fedele, +12

Cell Reports

MITOGENIC ACTIONS OF ENDOTHELIN‐1 AND EPIDERMAL GROWTH FACTOR IN CULTURED AIRWAY SMOOTH MUSCLE

Alastair G. Stewart, George Grigoriadis, Trudi Harris

Clinical and Experimental Pharmacology and Physiology

Mice lacking the transcription factor subunit Rel can clear an influenza infection and have functional anti-viral cytotoxic T cells but do not develop an optimal antibody response

Leanne Harling-McNabb, Georgia Deliyannis, David C. Jackson, +3

International Immunology

Albumin inhibits platelet‐activating factor (PAF)‐induced responses in platelets and macrophages: implications for the biologically active form of PAF

George Grigoriadis, Alastair G. Stewart

British Journal of Pharmacology

Deep profiling of apoptotic pathways with mass cytometry identifies a synergistic drug combination for killing myeloma cells

Charis E. Teh, Jianan Gong, David Segal, +12

Cell Death and Differentiation

Hematological MalignancyMedicineMalignant Blood DisorderApoptosisMyeloma Cells +9